NIH R01 · 2024
Role of the CTLH E3 ubiquitin ligase in breast cancer progression
Project Summary / Abstract HER2-positive breast cancers are highly aggressive and associated with poor prognosis. HER2-targeted therapy is the preferred treatment for these cancers, but drug resistance is a major problem. Our previous studies demonstrated that dysregulation of G protein coupled receptors, in particular, a subgroup of GPCRs that couple to G protein αi/o subunits (Gi/o-GPCRs), contributes to HER2-induced breast cancer initiation and progression. Targeting Gi/o-GPCR signaling blocks tumor progression and enhances the efficacy of HER2-targeted therapy. This proposal aims to delineate how dysregulated Gi/o-GPCR signaling may control HER2+ breast cancer progression through a…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.